Central Health

centralhealth.nl.ca

Central Health is the second largest health region in Newfoundland and Labrador, providing health and community services to approximately 20 per cent of the province’s population. Our 94,000 clients, patients, residents, and their families live in 177 communities in a region that extends from Charlottetown in the east, Fogo Island in the north, Harbour Breton in the south, to Baie Verte in the west.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AVM BIOTECHNOLOGY HAS FDA APPROVAL FOR CLINICAL TRIALS FOR PROMISING NEW CANCER TREATMENT

PR Newswire | April 14, 2020

news image

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM070...

Read More

INDUSTRIAL IMPACT

FEN INDUSTRIES EARNS USDA CERTIFIED BIOBASED PRODUCT LABEL FOR TERREPLENISH® SOIL MICROBES

FEN Industries | February 22, 2022

news image

FEN announced today that it has earned the U.S. Department of Agriculture (USDA) Certified Biobased Product label. The product, Terreplenish®, has 97% biobased content. Third-party verification for a product's biobased content is administered through the USDA BioPreferred Program, an initiative created by the Farm Bill. The primary goal of the BioPreferred Program is to increase the development, purchase, and use of biobased products. Biobased products have ...

Read More

CELL AND GENE THERAPY

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

news image

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More

CELL AND GENE THERAPY

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

news image

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More
news image

AVM BIOTECHNOLOGY HAS FDA APPROVAL FOR CLINICAL TRIALS FOR PROMISING NEW CANCER TREATMENT

PR Newswire | April 14, 2020

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM070...

Read More
news image

INDUSTRIAL IMPACT

FEN INDUSTRIES EARNS USDA CERTIFIED BIOBASED PRODUCT LABEL FOR TERREPLENISH® SOIL MICROBES

FEN Industries | February 22, 2022

FEN announced today that it has earned the U.S. Department of Agriculture (USDA) Certified Biobased Product label. The product, Terreplenish®, has 97% biobased content. Third-party verification for a product's biobased content is administered through the USDA BioPreferred Program, an initiative created by the Farm Bill. The primary goal of the BioPreferred Program is to increase the development, purchase, and use of biobased products. Biobased products have ...

Read More
news image

CELL AND GENE THERAPY

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More
news image

CELL AND GENE THERAPY

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More